Selecting an Antiarrhythmic Agent for Atrial Fibrillation Should Be a Patient-Specific, Data-Driven Decision

American Journal of Cardiology

Volumn 82, Issue 7 A, 1998, Pages 72N-81N

  Reiffel, James A ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; WARFARIN;

ALGORITHM; CARDIOVERSION; CLINICAL TRIAL; CONFERENCE PAPER; DEFIBRILLATION; DIRECT CURRENT; DRUG CHOICE; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL DECISION MAKING; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK BENEFIT ANALYSIS; SINUS RHYTHM;

ALGORITHMS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; HUMANS;

EID: 0031766180     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00588-8     Document Type: Article

References (65)

1. Blitzer M, Costeas C, Kassotis J, Reiffel JA. Rhythm management in atrial fibrillation with a primary emphasis on pharmacologic - part 1. PACE Pacing Clin Electrophysiol 1998;21:590-602.
2. Costeas C, Kassotic J, Blitzer M, Reiffel JA. Rhythm management in atrial fibrillation with a primary emphasis on pharmacologic - part 2. PACE Pacing Clin Electrophysiol 1998;21:742-752.
3. Kassotis J, Costeas C, Blitzer M, Reiffel JA. Rhythm management in atrial fibrillation with a primary emphasis on pharmacologic - part 3. PACE Pacing Clin Electrophysiol 1998;21:1133-1145.
4. Prystowsky EN, Benson W, Fuster V, Hart RG, Kay GN, Myerburg RH, Naccarelli GV, Wyse DG. Management of patients with atrial fibrillation. A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology of the American Heart Association. Circulation 1996;93:1262-1277.
5. Kerr CR, Boone J, Connolly SJ, Dorian P, Green M, Klein G, Newman D, Sheldon R, Talajie M. The Canadian registry of atrial fibrillation: a non-interventional follow-up of patients following the first diagnosis of AF. Am J Cardiol 1998;82:82N-85N.
6. Kowey P, Marinchak RA, Rials SJ, Heaney S, Bharucha DB. Atrial fibrillation trials: will they teach us what we need to know? Am J Cardiol 1998;82:86N-91N.
7. Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC Jr, Meissmer MC, Zoble RG, Wakefield LK, Perry KT, Vanderlught JT. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and flutter: a doseresponse study. J Am Coll Cardiol 1996;28:130-136.
8. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, Vanderlugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-1621.
9. Capucci A, Lenzi T, Boriani G, Trisolino G, Binetti N, Cavazza M, Fontana G, Magnani B. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70:69-72.
10. Capucci A, Boriani G, Botto GL, Lenzi T, Rubino I, Falcone C, Trisolino G, Della Cassa S, Binetti N, Cavazza M. Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol 1994;74:503-505.
11. Botto GL, Capucci A, Bonini W, Boriani G, Broffoni T, Barone P, Espureo M, Lombardi R, Molteni S, Ferrari G. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. Int J Cardiol 1997;58:55-61.
12. Boriani G, Capucci A, Lenzi T, Sanguinetti M, Magnani B. Propafenone for conversion of recent-onset atrial fibrillation: a controlled comparison between oral loading dose and intravenous administration. Chest 1995;108: 355-358.
13. Botto GL, Bonini W, Broffoni T, Molteni S, Lombardi R, Alfieri G, Barone P, Bernasconi G, Ferrari G. Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? PACE Pacing Clin Electrophysiol 1996;19:1939-1943.
14. Boriani G, Biffi M, Capucci A, Botto GL, Broffoni T, Rubino I, Della Casa S, Sanguinetti M, Magnoni B. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease: a randomized, controlled trial. Ann Intern Med 1997;126:621-625.
15. Boriani G, Capucci A, Botte GC. Different pharmacologic treatment for converting recent-onset atrial fibrillation: evaluation of 377 patients. (Abstr.) J Am Coll Cardiol 1996;27:80A.
16. Wijffels MC, Kirchoff CJ, Dorland R, Allessi MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-1968.
17. Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA, Weyman AE. Atrial enlargement as a consequence of atrial fibrillation. A prospective echo cardiographic study. Circulation 1995;92:I-114.
18. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillage H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation of atrial flutter. Am J Cardiol 1991; 68:335-341.
19. Juul-Moller S, Edvardsson AN, Rehnquist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation. Circulation 1990;82:1932-1939.
20. Boissel JP, Wolfe E, Gillet J, Soubrane A, Cavallaro A, Mazoyer G, Delahaye JP. Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. Eur Heart J 1981;2:49-55.
21. Sodermark T, Jonsson B, Olsson A, Oro L, Wallin H, Edhag O, Sjogren A, Danielsson M, Rosenhamer G. Effect of quinidine on maintaining sinus rhythm after cardioversion of atrial fibrillation or flutter. A multicenter study from Stockholm. Br Heart J 1975;37:486-492.
22. Hillestad L, Bjerkerlund C, Dale J, Maltau J, Storstein O. Quinidine in maintenance of sinus rhythm after electroversion of chronic atrial fibrillation. A controlled study. Br Heart J 1971;33:518-521.
23. Grande P, Sonne B, Pedersen A. A controlled study of digoxin and quinidine in patients DC reverted from atrial fibrillation to sinus rhythm. Circulation 1986;74:II-101.
24. Lloyd EA, Gersh BJ, Forman R. The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electro conversion from atrial fibrillation: a double-blind study comparing quinidine, disopyramide, and placebo. S Afr Med J 1984;65:367-369.
25. Zehender M, Hohnloser S, Muller B. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992;19:1054-1059.
26. Rasmussen K, Andersen A, Abrahamsen A, et al. Flecainide versus disopyramide in maintaining sinus rhythm following conversion of chronic atrial fibrillation. Eur Heart J 1998;9:I-52.
27. Karlson BW, Torstensson I, Abjorn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electro conversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 1988;9: 284-290.
28. Crijns HJGM, Gosselink ATM, Lie KI. Propafenone versus disopyramide for the maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation: a randomized double-blind study. Cardiovasc Drugs Ther 1996;2:145-152.
29. Reimold SC, Cantillon CO, Friedman PL, Antman EN. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71:558-563.
30. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman P. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988;12: 1011-1018.
31. Van Gelder IC, Crijns HJ, Van Gilst WH, Van Wijk LM, Hamer HP, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989;64:1317-1321.
32. Zarembski DG, Nolan PE, Slack MD, Caruso AC. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995;155:1885-1891.
33. Chun SH, Sager PT, Stevenson WG, Nadamanee K, Middelkauff HR, Singh BN. Long-term efficacy of amiodarone for maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
34. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986;57:124-127.
35. Szyszka A, Paluszkiewicz P, Baszynska H. Prophylactic treatment after electro conversion of atrial fibrillation in patients after cardiac surgery - a controlled two year follow-up study. JAm Coll Cardiol 1993;21:A-201.
36. Middlekauff HR, Wiener I, Stevenson WG. Low-dose amiodarone for atrial fibrillation. Am J Cardiol 1993;71(suppl):75F-81F.
37. Anderson JL. Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. Am J Cardiol 1992;70(suppl):11A-18A.
38. Chiemienti M, Cullen MT, Casadei G, for the Flecainide and Propafenone Italian Study (FAPIS) Investigators. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the flecainide and propafenone Italian study investigators. Am J Cardiol 1996;77(suppl):60A-65A.
39. Aliot E, Denjoy I, and the Flecainide AF French Study Group. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic atrial fibrillation/flutter. Am J Cardiol 1996;77(suppl):66A-71A.
40. Naccarelli GV, Dorian P, Hohnloser SH, Coumel P, for the flecainide multicenter atrial fibrillation study group. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996;77(suppl):53A-59A.
41. Bellandi F, Dabizzi RP, Niccoli L, Cantini F, Palchetti R. Propafenone and sotalol: long term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study. G Ital Cardiol 1996;26: 379-390.
42. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Pritchett EL. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo. Circulation 1989;80:1557-70.
43. Richiardi E, Gaita F, Greco C, Gaschino G, Comb Costa G, Rosettani E, Brusca A. Propafenone versus hydroquinidine in long-term pharmacological prophylaxis of atrial fibrillation. Cardiologica 1992;37:123-7.
44. Lee SH, Chen SA, Chiang CE, Tai CT, Wen ZC, Wang SP, Chang MS. Comparison of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. J Intern Med 1996;239:253-60.
45. Clementy J, Dulhoste MN, Laiter C, Denjoy I, Dos Santos P. Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine month follow-up of more than 500 patients. Am J Cardiol 1992;70(suppl):44A-49A.
46. Sonnhag C, Kallryd A, Nylander E, Ryden L. Long term efficacy of flecainide in paroxysmal atrial fibrillation. Acta Med Scand 1988;224:563-9.
47. Hammill SC, Wood DL, Gersh BJ, Osborn MJ, Holmes DR Jr. Propafenone for paroxysmal atrial fibrillation. Am J Cardiol 1988;61:473-474.
48. Leclercq JF, Chouty F, Denjoy J, Coumel P, Slama R. Flecainide in quinidine resistant atrial fibrillation. Am J Cardiol 1992;70(suppl):62A-65A.
49. Anderson JL, Platt ML, Guarnieri T, Fox TL, Maser MJ, Pritchet EL. Flecainide acetate for paroxysmal supraventricular tachycardias. Am J Cardiol 1994;74:578-584.
50. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993;72:280-287.
51. Julian DG, Camm AJ, Frangia G, Janse MJ, Munoz A, Schwartz PJ, Simon P. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction (EMIAT): European Myocardial Infarct Amiodarone Trial. Lancet 1997;349:667-674.
52. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations (CAMIAT): Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Lancet 1997;349:675-682.
53. Reiffel JA, Correia J. "In the absence of structural heart disease..." what is it and why does it matter as regards antiarrhythmic drug therapy? Am Heart J 1994;128:626-629.
54. Reiffel JA. The impact of structural heart disease on the selection of class III antiarrhythmics for atrial fibrillation and flutter. Am Heart J 1998; 135:551-556.
55. The CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction [special report]. N Engl J Med 1989;321:406-412.
56. Pritchett EL, Wilkinson WE. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol 1991;67:976-980.
57. Reimold SC. Avoiding drug problems. The safety of drugs for supraventricular tachycardia. Eur Heart J 1997;18(suppl C):C40-C44.
58. Teo KK, Yusus S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993;270:1589-1595.
59. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pitt B, Pratt CM, Rodda BE, Schwartz PJ, for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
60. The DIAMOND Study Group. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Clin Cardiol 1997;20:704-710.
61. Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;i:1142-1147.
62. Singh SN, Berk MR, Yellen LG, Zobel RG, Abramson D, Satler CA, Friedrich T. Efficacy and safety of oral dofetilide in maintaining normal sinus in patients with atrial fibrillation/flutter: a multicenter study. Circulation 1997;96: 1-383.
63. Doval HC, Nul DR, Grancelli HO, Varini SD, Soifer S, Corrado G, Dubner S, Scapin O, Perrone SV, for the Grupo de Estudio de la Sobrevide en la Insufficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-498.
64. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania P, Massie BM, Colling C, Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
65. Reiffel JA. Data-driven decisions: the importance of clinical trials in arrhythmia management. J Cardiovasc Pharmacol Thera 1996;1:79-88.